TD Cowen Maintains Buy on United Therapeutics, Raises Price Target to $660

TD Cowen analyst Joseph Thome has maintained a 'Buy' rating on United Therapeutics (NASDAQ: UTHR) and increased the price target from $575 to $660. This adjustment reflects a positive outlook for the company's performance.